文献速递白血病淋巴瘤

奥加伊妥珠单抗序贯贝林妥欧单抗治疗新诊断老年B细胞急性淋巴细胞白血病:Alliance研究A041703队列1结果

Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results.
PubMed 文献 · J Clin Oncol · 2025-09-30

本研究纳入33例60岁及以上未经治疗、Ph阴性、CD22阳性B细胞急性淋巴细胞白血病患者,接受最多2周期奥加伊妥珠单抗后4或5周期贝林妥欧单抗及鞘内甲氨蝶呤中枢预防。主要终点1年无事件生存率为75%(95%CI 61-92),总生存率85%(95%CI 73-98),复合完全缓解率在奥加伊妥珠单抗2周期后为85%、贝林妥欧单抗2周期结束时为97%。作者认为该方案应被视为标准治疗选择。

要点

  • 33例患者中位年龄71岁,复合完全缓解率在奥加伊妥珠单抗2周期后85%、贝林妥欧单抗2周期结束时97%。
  • 中位随访30个月,1年无事件生存率75%(95%CI 61-92),总生存率85%(95%CI 73-98)。
  • CD22表达较低或任一時間点可检测到可测量残留病灶者无事件生存期较短。

核心结论

  • 在60岁及以上未经治疗、Ph阴性、CD22阳性B细胞急性淋巴细胞白血病患者中,奥加伊妥珠单抗序贯贝林妥欧单抗而不维持化疗可获得高缓解率和优异无事件生存。
  • 鉴于该人群缺乏标准、安全且有效的治疗,作者认为该方案应被视为标准治疗选择。

研究设计与样本

  • Alliance研究A041703队列1,纳入年龄60岁及以上未经治疗、Ph阴性、CD22阳性B细胞急性淋巴细胞白血病患者。
  • 患者接受最多2周期奥加伊妥珠单抗,随后4或5周期贝林妥欧单抗,并接受鞘内甲氨蝶呤中枢神经系统预防。
  • 主要终点为1年无事件生存率;共33例符合条件患者,中位年龄71岁(范围60-84),中位CD22表达92%(范围21%-100%)。

主要发现

  • 33例中8例(24%)曾因其他癌症接受化疗或放疗,其中6例为多发性骨髓瘤。
  • 复合完全缓解率在奥加伊妥珠单抗2周期后为85%,在贝林妥欧单抗2周期结束时为97%。
  • 中位随访30个月,1年无事件生存率为75%(95%CI 61-92),总生存率为85%(95%CI 73-98)。
  • CD22表达较低或任一時間点可检测到可测量残留病灶者无事件生存期较短。

关键数值与推荐

  • 复合完全缓解率:奥加伊妥珠单抗2周期后85%,贝林妥欧单抗2周期结束时97%。
  • 1年无事件生存率75%(95%CI 61-92),1年总生存率85%(95%CI 73-98),中位随访30个月。
  • CD22表达较低或任一時間点可检测到可测量残留病灶与较短无事件生存期相关。

临床怎么用

  • 作者认为,在缺乏标准、安全且有效治疗的该人群中,奥加伊妥珠单抗序贯贝林妥欧单抗方案应被视为标准治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Older patients with ALL receiving conventional chemotherapy have poor survival due to toxic death and relapse. We hypothesized that a chemotherapy-free, targeted regimen using the anti-CD22 antibody-calicheamicin conjugate inotuzumab ozogamicin followed by the bispecific anti-CD19/CD3 T-cell engager blinatumomab would reduce toxic death and yield high rates of prolonged remission and survival. METHODS: Eligible patients were age 60 years and older with untreated, Philadelphia chromosome (Ph)-negative, CD22-positive, B-cell ALL. Patients received up to two cycles of inotuzumab ozogamicin followed by four or five cycles of blinatumomab with intrathecal methotrexate CNS prophylaxis. The primary end point was 1-year event-free survival (EFS). RESULTS: The 33 eligible patients had a median age of 71 years (range, 60-84) and a median CD22 expression of 92% (range, 21%-100%). Eight (24%) had previous chemotherapy or radiation for other cancers, six for multiple myeloma. The composite complete remission rate was 85% after two cycles of inotuzumab ozogamicin and 97% by the end of two cycles of blinatumomab. At a median follow-up of 30 months, the 1-year EFS and overall survival were 75% (95% CI, 61 to 92) and 85% (95% CI, 73 to 98), respectively. EFS was shorter with lower CD22 expression or detectable measurable residual disease at any time point. CONCLUSION: Inotuzumab ozogamicin then blinatumomab without maintenance chemotherapy in older patients with untreated, Ph-negative, CD22-positive, B-cell ALL yields a high remission rate and excellent EFS. Given the lack of standard, safe, and effective therapies in this population, the regimen should be considered a standard treatment option.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Wieduwilt MJ, Yin J, Kour O, et al. Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results. J Clin Oncol. 2025. PMID: 41026957. doi:10.1200/JCO-25-00307

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。